Intratect

Human Normal Immunoglobulin, the active ingredient in Intratect, is a Immunoglobulin (human) presented as a solution for injection for intravenous use. It treats primary and secondary immunodeficiency diseases, idiopathic thrombocytopenic purpura, Kawasaki disease, and helps prevent infections in immunocompromised patients.

GNH USA supplies Intratect as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Intratect is an intravenous immunoglobulin that replaces missing antibodies and modulates immune activity across several disease categories. - Primary immunodeficiency diseases: provides passive immunity to reduce infection risk. - Secondary immunodeficiency (e.g., due to chemotherapy): supplies IgG to support immune function. - Idiopathic thrombocytopenic purpura (ITP): modulates immune‑mediated platelet destruction. - Kawasaki disease: reduces inflammation and coronary artery complications. - Prevention of infections in immunocompromised patients: lowers incidence of bacterial and viral infections.

Intratect may cause a variety of adverse reactions ranging from mild to severe.

Common Side Effects: - Headache: mild to moderate discomfort. - Fever and chills: transient rise in body temperature. - Nausea: occasional upset stomach. - Fatigue: feeling of tiredness post‑infusion. - Infusion‑related reactions: flushing, erythema, or mild hypotension. - Muscle aches: soreness in limbs.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate care. - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Acute renal dysfunction: sudden loss of kidney function. - Aseptic meningitis: inflammation of meninges without infection. - Hemolytic anemia: destruction of red blood cells. - Severe thrombocytopenia: marked drop in platelet count.

Before initiating Intratect therapy, clinicians should evaluate patient history and monitor for potential complications. - Assess patient history: review prior reactions to immunoglobulin products. - Monitor infusion rate: start slowly and increase as tolerated to reduce reactions. - Screen for renal impairment: adjust volume and monitor kidney function. - Evaluate hypercoagulable risk: consider thrombosis history before infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with several medications and vaccines, requiring careful management.

Major Interactions (Avoid): - Live attenuated vaccines: may be less effective when administered concurrently. - Anticoagulants (e.g., warfarin): can alter INR and increase bleeding risk. - Immunosuppressants (e.g., rituximab): may diminish therapeutic response.

Moderate Interactions (Monitor Closely): - Corticosteroids: combined use may raise infection susceptibility. - Diuretics: increased risk of volume overload. - ACE inhibitors: potential additive effect on renal function.